John Bishop
Chief Tech/Sci/R&D Officer bij LYRA THERAPEUTICS, INC.
Vermogen: - $ op 31-03-2024
Profiel
John E.
Bishop's career history includes current and former positions as well as education.
Currently, he is the Chief Technology Officer at Lyra Therapeutics, Inc. Prior to this, he held the position of Chief Technology Officer at Forma Therapeutics Holdings, Inc. from 2021 to 2023.
He also served as the Senior Vice President-Pharmaceutical Sciences at Epizyme, Inc. from 2017 to 2021 and at Genocea Biosciences, Inc. from 2016 to 2017.
Additionally, he worked as the Senior Vice President-Pharmaceutical Services at Momenta Pharmaceuticals, Inc. from 2004 to 2016.
Earlier in his career, he was the Director & Head-Process Development at Millennium Pharmaceuticals, Inc. from 2000 to 2004 and the Leader-Process Research & Development at DuPont Merck Pharmaceutical Co. from 1994 to 2000.
Dr. Bishop's education includes an undergraduate degree from Tufts University, an MBA from Northeastern University, and a doctorate from the University of California, Berkeley.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
LYRA THERAPEUTICS, INC.
-.--% | 30-01-2024 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van John Bishop
| Bedrijven | Functie | Begin |
|---|---|---|
| LYRA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 27-02-2023 |
Eerdere bekende functies van John Bishop
| Bedrijven | Functie | Einde |
|---|---|---|
| FORMA THERAPEUTICS HOLDINGS, INC. | Chief Tech/Sci/R&D Officer | 01-02-2023 |
| EPIZYME, INC. | Corporate Officer/Principal | 01-05-2021 |
| GENOCEA BIOSCIENCES, INC. | Corporate Officer/Principal | 01-05-2017 |
| MOMENTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-05-2016 |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Director/Board Member | 01-10-2004 |
Opleiding van John Bishop
| Tufts University | Undergraduate Degree |
| Northeastern University | Masters Business Admin |
| University of California, Berkeley | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| LYRA THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 5 |
|---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Forma Therapeutics Holdings, Inc.
 Forma Therapeutics Holdings, Inc. Pharmaceuticals: MajorHealth Technology Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. engages in the research, development and commercialization of novel therapeutics for the treatment of hematologic diseases and cancers. Its product pipeline consists of FT-4202 for the treatment of sickle cell disease and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company was founded by Michael A. Foley in December 2011 and is headquartered in Watertown, MA. | Health Technology |
DuPont Merck Pharmaceutical Co.
 DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a private company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Health Technology |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
